Detailed Coverage

Dr. Reddy's Laboratories Q1FY27 Financial Results

Dr. Reddy's Laboratories reported a Profit After Tax of ₹443.5 crore for the quarter ended June 30, 2026.
Revenue from operations stood at ₹8,070.5 crore.

Reader Takeaway: Base business growth is strong, but API issues and regulatory concerns create near-term margin pressure.

What just happened

Dr. Reddy's Laboratories announced its unaudited consolidated financial results for the first quarter of fiscal year 2027 (Q1FY27). The company posted a Profit After Tax (PAT) of ₹443.5 crore and Revenue from Operations of ₹8,070.5 crore. EBITDA was reported at ₹1,008.8 crore, and Profit Before Tax (PBT) was ₹552.6 crore.

Why this matters

The financial performance was significantly impacted by a provision of approximately ₹239.7 crore related to an unexpected issue with the active pharmaceutical ingredient (API) for semaglutide. This provision reduced gross profit, EBITDA, and PBT margins by about 3% for the quarter. Despite these setbacks, the company highlighted that its underlying base business demonstrated healthy double-digit growth across key geographies, excluding the impact of declining Lenalidomide revenues and the semaglutide API issue.

The backstory

This quarter reflects a transitional phase for Dr. Reddy's as it manages the decline in revenues from its Lenalidomide product and addresses temporary supply chain challenges. The company also noted a USFDA Form 483 with seven observations following an inspection at its biologics manufacturing facility in Bachupally, Hyderabad, in June 2026. Management confirmed that responses to the USFDA have been submitted.

What changes now

Dr. Reddy's has entered into a strategic agreement with Innoviva Specialty Therapeutics to develop and commercialize XACDURO for hospital-acquired bacterial pneumonia in select markets. Additionally, Dr. Sridevi Khambhampaty has been appointed as the Global Head of Biologics and Senior Management Personnel. The company also appointed M/s Deloitte Haskins & Sells, LLP as its Independent Registered Public Accounting Firm for US SEC filings.

Risks to watch

Key risks for investors include the successful remediation of the biologics manufacturing facility following the USFDA inspection and the resolution of the quality issues concerning the semaglutide API. These operational challenges could continue to affect margins and regulatory compliance in the short term.

Peer comparison

While specific peer results for Q1FY27 are not yet available, Dr. Reddy's performance highlights the challenges faced by Indian pharmaceutical companies in managing API quality, regulatory compliance, and product exclusivity cycles. The company's ability to maintain growth in its base business amid these pressures is a key differentiator.

Context metrics (time-bound)

• Revenue from Operations (Q1FY27): ₹8,070.5 crore
• Profit After Tax (Q1FY27): ₹443.5 crore
• Provision for semaglutide API issue: ₹239.7 crore
• Net Cash Surplus (as on June 30, 2026): ₹3,060 crore
• Operating Working Capital (as on June 30, 2026): ₹14,350 crore

What to track next

Investors will be closely monitoring the company's progress in addressing the USFDA observations and resolving the semaglutide API supply quality issue. Future updates on regulatory clearances and supply chain stability will be crucial for assessing the company's performance trajectory.